source
- Kolon’s cell-based gene therapy misses key endpoints in phase 3 osteoarthritis trialKolon TissueGene reported that its phase 3 study of TG‑C, a cell‑based gene therapy for knee osteoarthritis, failed to meet its co‑primary endpoints. Patients receiving the therapy showed no statis…
- Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromabScribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…